Press Releases

Date Title  
Toggle Summary National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer
Pivotal Study of 1500 Patients Could Lead to Change in Practice Guidelines SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective,
Toggle Summary Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx
Adds to Natera's Extensive Suite of More Than 200 Issued and Pending Patents SAN CARLOS, Calif. , Jan. 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S.
Toggle Summary Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer
Study to quantify changes in post-surgical treatment and impact of early relapse detection using Signatera test SAN CARLOS, Calif. , Jan. 9, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called
Toggle Summary Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif. , Jan. 8, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday,
Toggle Summary Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents
Exceeds 2019 goal of $40-$50 million in cumulative contracts with pharmaceutical companies and extends leadership in ctDNA MRD SAN CARLOS, Calif. , Jan. 6, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of
Toggle Summary Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test
Coverage Expanded Beyond Initial Draft Local Coverage Decision SAN CARLOS, Calif. , Dec. 19, 2019 /PRNewswire/ -- Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage
Toggle Summary Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies
First published evidence showing that individual fetal fraction measurement is a critical determinant of test reliability SAN CARLOS, Calif. , Nov. 27, 2019 /PRNewswire/ --   Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in
Toggle Summary Natera Reports Third Quarter 2019 Financial Results
SAN CARLOS, Calif. , Nov. 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2019 and provided an update on recent business progress.
Toggle Summary Natera Announces Third Quarter 2019 Earnings Conference Call
SAN CARLOS, Calif. , Oct. 30, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2019 , after the market close on November 6, 2019 .
Toggle Summary Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , Oct. 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 shares of its common stock at a price to the public of $35.00 per share.

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.